Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Too Soon To Say If US FDA Device Reforms Are Working, Says Independent Report

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has adopted all of the recommendations that consulting firm Booz Allen Hamilton has made in the past two years to improve its medical device review process, but it is still too early to say if the changes have improved overall performance.

You may also be interested in...



Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations

FDA and industry have finally struck a tentative deal that, with Congressional approval, aims to raise nearly a billion dollars over five years. It also holds FDA to higher quality metrics while starting a pilot project to use real-world evidence in tracking devices on the market.

The EU’s New Batteries Regulation: When And How Its Requirements Will Impact Medtech

The EU Batteries Regulation is yet another legal instrument medical device manufacturers must address over the coming years alongside the core Medical Device and IVD Regulations.

Mental Health Top Of Mind For Increasingly Health-Anxious Brits, Kaizo Survey Finds

Worryingly, however, British consumers are also increasingly turning to social media for health information, and rejecting it if it conflicts with what they believe, or if it is not based on personal experience. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel